A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 mu g versus once-daily vilanterol 25 mu g to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD

Siler Thomas M.; Nagai Atsushi; Scott-Wilson Catherine A.; Midwinter Dawn A.; Crim Courtney

首页> 外文期刊>Respiratory medicine >A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 mu g versus once-daily vilanterol 25 mu g to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD

【24h】

A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 mu g versus once-daily vilanterol 25 mu g to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD

机译：一次每日氟酸甲酸呋喃/维替醇100/25μg的随机，期III试验与一次每日Vilantolol25μg评估氟酮源于COPD患者组合的氟酮源性肺功能的贡献

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The contribution of fluticasone furoate (FF) on lung function in the FF/vilanterol (VI) 100/25 jig combination has been demonstrated numerically, but not statistically.

机译：背景：在FF / Vilantolol（VI）100/25 jig组合中的肺功能对肺功能（FF）的贡献已经在数值上进行了数值，但没有统计学。

著录项

来源
《Respiratory medicine》 |2017年第2017期|共10页
作者
Siler Thomas M.; Nagai Atsushi; Scott-Wilson Catherine A.; Midwinter Dawn A.; Crim Courtney;
展开▼
作者单位

Midwest Chest Consultants PC 330 First Capitol Dr Suite 470 St Charles MO 63301 USA;

Shin Yurigaoka Gen Hosp Res Inst Resp Dis Kawasaki Kanagawa Japan;

GlaxoSmithKline Res Triangle Pk NC USA;

GlaxoSmithKline Stockley Pk Uxbridge Middx England;

GlaxoSmithKline Res Triangle Pk NC USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类呼吸系及胸部疾病;
关键词
Fluticasone furoate; Vilanterol; COPD; Lung function; Moderate/severe COPD exacerbation;

机译：氟替辛呋喃酸盐;类化合物;COPD;肺功能;中度/严重COPD加剧;

相似文献

外文文献

1. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 mu g versus once-daily vilanterol 25 mu g to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD [J] . Siler Thomas M., Nagai Atsushi, Scott-Wilson Catherine A., Respiratory medicine . 2017,第期

机译：一次每日氟酸甲酸呋喃/维替醇100/25μg的随机，期III试验与一次每日Vilantolol25μg评估氟酮源于COPD患者组合的氟酮源性肺功能的贡献
2. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy [J] . Gillian Stynes, Henrik Svedsater, Jaro Wex, Respiratory Research . 2015,第1期

机译：每日一次糠酸氟替卡松/维兰特罗100/25 mcg与每日两次联合治疗COPD –临床疗效的混合治疗比较
3. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD [J] . KerwinE.M., Scott-WilsonC., SanfordL., Respiratory medicine . 2013,第4期

机译：糠酸氟替卡松/维兰特罗（50/25μg; 100/25μg）对COPD肺功能的随机试验
4. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy [O] . Gillian Stynes, Henrik Svedsater, Jaro Wex, 2015

机译：每日一次糠酸氟替卡松/维兰特罗100/25 mcg与每日两次联合治疗COPD –临床疗效的混合治疗比较
5. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD [O] . Thomas M. Siler, Atsushi Nagai, Catherine A. Scott-Wilson, 2017

机译：一次每日氟酸甲酸呋喃/维替者100/25μg与一次每日Vilantolol25μg的随机，期III试验，以评估氟酮源于COPD患者组合中氟酮源性的肺功能的贡献

A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 mu g versus once-daily vilanterol 25 mu g to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD

摘要

著录项

相似文献

相关主题

期刊订阅